Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL TRIALS
      • AUTISM
      • INSOMNIA
      • CHRONIC PAIN
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL TRIALS
      •                 - AUTISM
      •                 - INSOMNIA
      •                 - CHRONIC PAIN
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2021
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme

By Zelira TherapeuticsSeptember 16, 2020articles-2020

Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme

Medicinal cannabis trial could help retired AFL players manage chronic pain
Zelira Therapeutics’ insomnia treatment gets TGA tick

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
21 Apr

ASX Announcement: March 2021 Quarterly Report. Read full announcement here http://ow.ly/Xuxq50EtOfV

#zeliratx #zeliratherapeutics #zelira #ZLD #ZLDAX #ZLDAF #Zelirainsomnia #Zeliraautism #zeliraHOPE #zelirazenivol

Twitter 1384774751902748672
Load More...

CONTACT US

    Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.